1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AC Immune SA
  6. News
  7. Summary
    ACIU   CH0329023102

AC IMMUNE SA

(ACIU)
  Report
Delayed Nasdaq  -  04:00 2022-08-19 pm EDT
3.330 USD    0.00%
08/12AC Immune To Host Key Opinion Leader Webinar On Vaccinations To Treat And Prevent Alzheimer's And Parkinson's Diseases
AQ
08/11AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer's and Parkinson's Diseases
AQ
08/02AC IMMUNE : Detailed data from the phase II Crenezumab Alzheimer's Prevention Initiative Study in Autosomal Dominant Alzheimer's Disease Presented at AAIC - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

AC Immune Shares Fall Premarket on Alzheimer's Study Miss

06/16/2022 | 04:42am EDT

By Colin Kellaher


Shares of AC Immune SA tumbled more than 15% in premarket trading Thursday after the clinical-stage biopharmaceutical company reported disappointing results from a study in Alzheimer's disease.

The Lausanne, Switzerland, company and its partner, Roche Holdings AG's Genentech unit, said the study evaluating the potential of the investigational drug crenezumab to slow or prevent Alzheimer's in cognitively unimpaired people who carry a specific genetic mutation that causes early onset of the memory-robbing disease missed its key goals.

The companies, which have been working together since 2005, said crenezumab didn't show a statistically significant clinical benefit in either of its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function.

AC Immune and Genentech said small numerical differences favoring crenezumab were observed across the study's co-primary and multiple secondary and exploratory endpoints, but that they weren't statistically significant.

However, AC Immune said the differences, along with crenezumab's safety profile, warrant further analyses of the data.

AC Immune's U.S.-listed shares, which closed Wednesday at $2.86, were recently down 15.4% to $2.42 in premarket trading.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

06-16-22 0642ET

Stocks mentioned in the article
ChangeLast1st jan.
AC IMMUNE SA 0.00% 3.33 Delayed Quote.-32.73%
ROCHE HOLDING AG 1.06% 323.35 Delayed Quote.-15.60%
All news about AC IMMUNE SA
08/12AC Immune To Host Key Opinion Leader Webinar On Vaccinations To Treat And Prevent Alzhe..
AQ
08/11AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzhe..
AQ
08/02AC IMMUNE : Detailed data from the phase II Crenezumab Alzheimer's Prevention Initiative S..
PU
08/02Detailed Data From the Phase II Crenezumab Alzheimer's Prevention Initiative Study in A..
AQ
08/02AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Preve..
CI
07/28AC IMMUNE : Condensed Consolidated Balance Sheets (Unaudited) - Form 6-K
PU
07/28AC IMMUNE : Q2 Earnings Snapshot
AQ
07/28AC Immune SA Reports Earnings Results for the Second Quarter and Six Months Ended June ..
CI
07/28AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update
AQ
07/25AC Immune Announces Upcoming Presentations At The Alzheimer's Association International..
AQ
More news
Analyst Recommendations on AC IMMUNE SA
More recommendations
Financials
Sales 2022 1,60 M 1,67 M 1,67 M
Net income 2022 -79,9 M -83,3 M -83,3 M
Net Debt 2022 - - -
P/E ratio 2022 -3,30x
Yield 2022 -
Capitalization 247 M 257 M 257 M
Capi. / Sales 2022 154x
Capi. / Sales 2023 4,50x
Nbr of Employees -
Free-Float 44,6%
Chart AC IMMUNE SA
Duration : Period :
AC Immune SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AC IMMUNE SA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,19 CHF
Average target price 10,18 CHF
Spread / Average Target 219%
EPS Revisions
Managers and Directors
Andrea Pfeifer Chief Executive Officer & Director
Christopher Roberts Chief Financial Officer & Associate VP-Finance
Douglas E. Williams Chairman
Marie Kosco-Vilbois Chief Scientific Officer
Piergiorgio Donati Chief Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
AC IMMUNE SA-32.73%257
MODERNA, INC.-40.94%58 680
LONZA GROUP AG-24.63%44 689
IQVIA HOLDINGS INC.-15.28%44 542
SEAGEN INC.11.04%31 186
ALNYLAM PHARMACEUTICALS, INC.31.77%26 820